OneDigital Investment Advisors LLC purchased a new stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 3,164 shares of the company's stock, valued at approximately $288,000.
Other institutional investors have also recently added to or reduced their stakes in the company. FMR LLC increased its holdings in shares of BioNTech by 22.2% during the fourth quarter. FMR LLC now owns 7,701,476 shares of the company's stock valued at $877,583,000 after acquiring an additional 1,401,547 shares in the last quarter. BNP Paribas Financial Markets bought a new stake in shares of BioNTech during the fourth quarter valued at approximately $69,999,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its holdings in shares of BioNTech by 632.6% during the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 501,897 shares of the company's stock valued at $57,191,000 after acquiring an additional 433,388 shares in the last quarter. Capital International Investors increased its holdings in shares of BioNTech by 38.6% during the fourth quarter. Capital International Investors now owns 1,415,566 shares of the company's stock valued at $161,304,000 after acquiring an additional 394,434 shares in the last quarter. Finally, Franklin Resources Inc. grew its holdings in BioNTech by 3,942.1% during the fourth quarter. Franklin Resources Inc. now owns 136,786 shares of the company's stock worth $15,587,000 after buying an additional 133,402 shares in the last quarter. 15.52% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several equities research analysts recently issued reports on the company. Leerink Partners set a $112.00 price target on BioNTech in a report on Monday, June 2nd. Citigroup reiterated a "buy" rating and set a $140.00 price target (down previously from $145.00) on shares of BioNTech in a report on Tuesday, May 6th. HC Wainwright reiterated a "buy" rating and set a $138.00 price target on shares of BioNTech in a report on Wednesday, June 25th. The Goldman Sachs Group initiated coverage on BioNTech in a report on Thursday, May 29th. They set a "neutral" rating and a $110.00 price target for the company. Finally, Wall Street Zen upgraded BioNTech from a "sell" rating to a "hold" rating in a research note on Saturday, June 7th. Five equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, BioNTech presently has a consensus rating of "Moderate Buy" and an average price target of $136.58.
Read Our Latest Stock Report on BioNTech
BioNTech Price Performance
BNTX traded up $1.84 during trading on Wednesday, reaching $112.49. 786,503 shares of the company were exchanged, compared to its average volume of 941,517. The company's 50-day moving average is $104.07 and its two-hundred day moving average is $106.76. The company has a market cap of $27.04 billion, a price-to-earnings ratio of -33.09 and a beta of 1.29. The company has a quick ratio of 10.02, a current ratio of 10.18 and a debt-to-equity ratio of 0.01. BioNTech SE Sponsored ADR has a 12-month low of $76.53 and a 12-month high of $131.49.
About BioNTech
(
Free Report)
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.
Read More
Before you consider BioNTech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioNTech wasn't on the list.
While BioNTech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
